Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi) vs. Afatinib or erlotinib.

Adam BarsoukOmar ElghawyAlec HeidlaufConnie YuLucy WangDavid YangMartin KurianKeshav GoelLynn RushkinAnna Anran HuangLauren Reed-GuyBenjamin BleibergLova SunAditi SinghRoger B CohenCharu AggarwalMelina MarmarelisCorey Langer

Published in: Lung cancer (Amsterdam, Netherlands) (2024)

In a large real-world analysis, osi demonstrated superior progression-free and overall survival and improved tolerability compared to afatinib or erlotinib for atypical EGFR-mutated mNSCLC.

Keyphrases

epidermal growth factor receptor
advanced non small cell lung cancer
tyrosine kinase
small cell lung cancer
squamous cell carcinoma
open label
clinical trial
type diabetes
double blind
study protocol
placebo controlled